iTeos Therapeutics 주식 가격. ITOS - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

7.265

매수가

7.26

매도가

7.27

거래량

96,897

7.17 일간 변동폭 7.30

7.09 52주 범위 18.75

market_cap

265.419M

전일 종가

7.32

개장가

7.26

최근 거래 시간

7.265

마지막 거래 시간

01:45:36

재정 규모

US$ 701,143

VWAP

7.236

평균 볼륨(3m)

566,343

발행 주식

36,533,918

배당수익률

주가수익률

-2.35

주당순이익(EPS)

-3.08

매출

12.6M

순이익

-112.64M

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. 더 보기

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.iteostherapeutics.com

본부

Wilmington, Delaware, USA

설립됨

iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker ITOS. The last closing price for iTeos Therapeutics was US$7.32. Over the last year, iTeos Therapeutics shares have traded in a share price range of US$ 7.09 to US$ 18.75.

iTeos Therapeutics currently has 36,533,918 shares in issue. The market capitalisation of iTeos Therapeutics is US$267.43 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -2.35.

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts...

Form 4 - Statement of changes in beneficial ownership of securities

iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2...

Form 8-K - Current report

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.115	-1.55826558266	7.38	7.53	7.17	318506	7.37134313	CS
4	-1.145	-13.614744352	8.41	8.73	7.09	511019	7.75881781	CS
12	-2.765	-27.5672981057	10.03	10.22	7.09	566343	8.57040649	CS
26	-7.565	-51.0114632502	14.83	18.13	7.09	528351	11.24805639	CS
52	-3.655	-33.4706959707	10.92	18.75	7.09	444222	12.23422699	CS
156	-38.695	-84.1927763272	45.96	52.43	7.09	410376	17.79222125	CS
260	-12.435	-63.1218274112	19.7	52.43	7.09	361680	20.39929701	CS

ITOS - Frequently Asked Questions (FAQ)

What is the current iTeos Therapeutics share price?

The current share price of iTeos Therapeutics is US$ 7.265

How many iTeos Therapeutics shares are in issue?

iTeos Therapeutics has 36,533,918 shares in issue

What is the market cap of iTeos Therapeutics?

The market capitalisation of iTeos Therapeutics is USD 267.43M

What is the 1 year trading range for iTeos Therapeutics share price?

iTeos Therapeutics has traded in the range of US$ 7.09 to US$ 18.75 during the past year

What is the PE ratio of iTeos Therapeutics?

The price to earnings ratio of iTeos Therapeutics is -2.35

What is the cash to sales ratio of iTeos Therapeutics?

The cash to sales ratio of iTeos Therapeutics is 21.06

What is the reporting currency for iTeos Therapeutics?

iTeos Therapeutics reports financial results in USD

What is the latest annual turnover for iTeos Therapeutics?

The latest annual turnover of iTeos Therapeutics is USD 12.6M

What is the latest annual profit for iTeos Therapeutics?

The latest annual profit of iTeos Therapeutics is USD -112.64M

What is the registered address of iTeos Therapeutics?

The registered address for iTeos Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the iTeos Therapeutics website address?

The website address for iTeos Therapeutics is www.iteostherapeutics.com

Which industry sector does iTeos Therapeutics operate in?

iTeos Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
NXUNXU Inc	US$ 1.4516 (496.38%)	359.04M
WATTEnergous Corporation	US$ 1.5806 (284.39%)	157.58M
INTZIntrusion Inc	US$ 5.68 (162.96%)	107.97M
CYNCYNGN Inc	US$ 1.299 (106.88%)	55.86M
HOLOMicroCloud Hologram Inc	US$ 4.31 (79.58%)	84.35M
ABPAbpro Holdings Inc	US$ 2.02 (-55.01%)	1.23M
TRAWTraws Pharma Inc	US$ 7.75 (-42.25%)	834.64k
LITMSnow Lake Resources Ltd	US$ 1.13 (-29.38%)	42.42M
LGHLWLion Group Holding Ltd	US$ 0.0052 (-25.71%)	54.71k
BITSGlobal X Blockchain and Bitcoin Stratagy ETF	US$ 66.5854 (-24.73%)	7.5k
NXUNXU Inc	US$ 1.4591 (499.47%)	359.09M
VINCVincerx Inc	US$ 0.3497 (80.26%)	286.42M
XTIAXTI Aerospace Inc	US$ 0.03995 (1.14%)	163.36M
WATTEnergous Corporation	US$ 1.5883 (286.26%)	157.58M
INTZIntrusion Inc	US$ 5.675 (162.73%)	107.98M